News & Updates

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025 byJairia Dela Cruz

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025
Low-dose aspirin halves recurrence risk in select CRC patients
Low-dose aspirin halves recurrence risk in select CRC patients
28 Feb 2025 byAudrey Abella

In colorectal cancer (CRC) patients harbouring mutations in the PI3K pathway, adjuvant treatment with aspirin 160 mg daily reduced the recurrence rate by over 50 percent, according to the 3-year results from the ALASCCA trial.

Low-dose aspirin halves recurrence risk in select CRC patients
28 Feb 2025